This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, B. P. Articles by Woodell, J. Search for Related Content PubMed PubMed Citation Articles by Rubin, B. P. Articles by Woodell, J.

A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E

Departments of ¹ Pathology, ² Radiation Oncology and Immunology, and ³ Comparative Medicine, University of Washington Medical Center, Seattle, Washington and ⁴ Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Brian P. Rubin, Department of Anatomic Pathology, University of Washington Medical Center, 1959 Northeast Pacific Street, Box 356100, Seattle, WA 98195. Phone: 206-598-5024; Fax: 206-598-8697; E-mail: bprubin{at}u.washington.edu.

A mouse model of gastrointestinal stromal tumor (GIST) has been developed by a knock-in gene targeting strategy, which introduced a Kit gene K641E mutation, originally identified in sporadic human GISTs and in the germ line of familial GIST syndrome patients. Homozygous and heterozygous Kit K641E mice develop gastrointestinal pathology with complete penetrance and all Kit K641E homozygotes die by age 30 weeks due to gastrointestinal obstruction by hyperplastic interstitial cells of Cajal (ICC) or GISTs. Heterozygous mice have less extensive ICC hyperplasia and smaller GISTs, suggesting a dose-response relationship between oncogenically activated Kit and ICC proliferation. Immunoprecipitation and Western blotting reveal GISTs to contain abundant phosphorylated/activated Kit. In addition to ICC hyperplasia and GISTs, homozygous Kit K641E mice exhibit loss-of-function Kit phenotypes, including white coat color, decreased numbers of dermal mast cells, and sterility, indicating that despite its oncogenic activity the mutant form cannot accomplish many activities of the wild-type gene. Kit K641E reproduces the pathology associated with the familial GIST syndrome and thus is an excellent model to study Kit pathway activation, ICC biology, GIST pathogenesis, and preclinical validations of GIST therapies and mechanisms of drug resistance.

This article has been cited by other articles:

				P. P. Lin, M. K. Pandey, F. Jin, A.K. Raymond, H. Akiyama, and G. Lozano Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice Carcinogenesis, October 1, 2009; 30(10): 1789 - 1795. [Abstract] [Full Text] [PDF]

				M. C. Heinrich, S. George, S. Bauer, and J. A. Fletcher Optimizing the Treatment of Gastrointestinal Stromal Tumors: The Roles of Tumor Genotyping, Imatinib Blood-level Testing, and New Therapeutic Strategies ASCO Educational Book, January 1, 2009; 2009(1): 694 - 699. [Abstract] [Full Text] [PDF]

				D. Gasparotto, S. Rossi, I. Bearzi, C. Doglioni, A. Marzotto, J. L. Hornick, A. Grizzo, C. Sartor, A. Mandolesi, R. Sciot, et al. Multiple Primary Sporadic Gastrointestinal Stromal Tumors in the Adult: An Underestimated Entity Clin. Cancer Res., September 15, 2008; 14(18): 5715 - 5721. [Abstract] [Full Text] [PDF]

				S. Tabone-Eglinger, F. Subra, H. El Sayadi, L. Alberti, E. Tabone, J.-P. Michot, N. Theou-Anton, A. Lemoine, J.-Y. Blay, and J.-F. Emile KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors Clin. Cancer Res., April 15, 2008; 14(8): 2285 - 2294. [Abstract] [Full Text] [PDF]